Our analysis showed that PD-L1 expression was generally lower on cancer cells (CD45-FAP-CD31-) compared to immune cells (CD45+) (Figures 2B, C), but with some tumor models such as CT26 having a relatively high level of PD-L1 expression on cancer cells (Figure 2B). Here, PTPRC is linked to neoplasm.